Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Etentamig
DRUG: Carfilzomib
DRUG: Pomalidomide
DRUG: Elotuzumab
DRUG: Selinexor
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

AbbVie